organization · Reporting owner
Vida Ventures III, L.P.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Attovia Therapeutics, Inc.ATTO · Entity 4984 | 10% owner | August 04, 2026 | August 05, 2026 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | 10% owner | February 12, 2024 | February 15, 2024 |
| Vigil Neuroscience, Inc.VIGL · Entity 11675 | 10% owner | January 11, 2022 | January 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Attovia Therapeutics, Inc.
Report date August 04, 2026 · Filed August 05, 2026
Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III-A, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock on a 9.29-for-1 basis and has no expiration date. All shares of Series C Preferred Stock will automatically convert on a 9.29-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim, and Rajul Jain are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III-A, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock on a 9.29-for-1 basis and has no expiration date. All shares of Series C Preferred Stock will automatically convert on a 9.29-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series C Preferred Stock is convertible into shares of the Issuer's Common Stock on a 9.29-for-1 basis and has no expiration date. All shares of Series C Preferred Stock will automatically convert on a 9.29-for-1 basis into shares of Common Stock upon the closing of the Issuer's initial public offering of its Common Stock without payment of additional consideration.
F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim, and Rajul Jain are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").
F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment, and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Kyverna Therapeutics, Inc.
Report date February 12, 2024 · Filed February 15, 2024
Jointly reported with Vida Ventures, LLC, Vida Ventures GP III, L.L.C., Vida Ventures III-A, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures, LLC | 4,523,924 |
Reported balance
After 2024-02-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-12 · Conversion · Acquired 4,523,924 · Balance 4,523,924 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III, L.P. | 252,553 |
Reported balance
After 2024-02-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-02-12 · Purchase · Acquired 252,553 · Balance 252,553 F3: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III-A, L.P. | 583 |
Reported balance
After 2024-02-12 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-02-12 · Purchase · Acquired 583 · Balance 583 F4: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series A-1 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures, LLC | 0 |
Reported balance
After 2024-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-12 · Conversion · Disposed 4,401,771 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. |
| Series A-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures, LLC | 0 |
Reported balance
After 2024-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-12 · Conversion · Disposed 8,830,901 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures, LLC | 0 |
Reported balance
After 2024-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-12 · Conversion · Disposed 7,356,162 · Balance 0 F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
F3: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F5: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
Vigil Neuroscience, Inc.
Report date January 11, 2022 · Filed January 12, 2022
Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III-A, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III, L.P. | 5,004,393 |
Last balance in matching sequence
After 2022-01-11 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-01-11 · Conversion · Acquired 3,333,245 · Balance 3,333,245 F1: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F2: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 3 · 2022-01-11 · Purchase · Acquired 1,671,148 · Balance 5,004,393 F4: On January 11, 2022, Vida III purchased 1,671,148 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering. F2: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III-A, L.P. | 11,536 |
Last balance in matching sequence
After 2022-01-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2022-01-11 · Conversion · Acquired 7,684 · Balance 7,684 F1: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F3: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 4 · 2022-01-11 · Purchase · Acquired 3,852 · Balance 11,536 F5: On January 11, 2022, Vida III-A purchased 3,852 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering. F3: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III, L.P. | 0 |
Reported balance
After 2022-01-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-11 · Conversion · Disposed 9,243,756 · Balance 0 F1: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F2: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III-A, L.P. | 0 |
Reported balance
After 2022-01-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-01-11 · Conversion · Disposed 21,310 · Balance 0 F1: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F3: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date.
F2: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F3: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4: On January 11, 2022, Vida III purchased 1,671,148 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.
F5: On January 11, 2022, Vida III-A purchased 3,852 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LB PHARMACEUTICALS INC
Report date September 12, 2025 · Filed September 16, 2025
Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III-A, L.P., Belldegrun Arie, Vida Ventures Management Co. LLC
Section 16 reporting ended · disclosed 2025-09-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III, L.P. | 880,214 |
Last balance in matching sequence
After 2025-09-12 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-09-12 · Conversion · Acquired 547,648 · Balance 547,648 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 3 · 2025-09-12 · Purchase · Acquired 332,566 · Balance 880,214 F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures III-A, L.P. | 2,029 |
Last balance in matching sequence
After 2025-09-12 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2025-09-12 · Conversion · Acquired 1,262 · Balance 1,262 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 4 · 2025-09-12 · Purchase · Acquired 767 · Balance 2,029 F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III, L.P. | 0 |
Reported balance
After 2025-09-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-09-12 · Conversion · Disposed 13,302,666 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Vida Ventures III-A, L.P. | 0 |
Reported balance
After 2025-09-12 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-09-12 · Conversion · Disposed 30,667 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Vida Ventures Management Co. LLC | 1,434 |
Reported balance
Holding disclosure · report date 2025-09-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,434 F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.
F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").
F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionSeries C Preferred Stock · Derivative | 30,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 7 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionSeries C Preferred Stock · Derivative | 13,302,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · derivative · entry 6 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 547,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.exercise_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | PurchaseCommon Stock | 767 | $15.00 | $11,505.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 4 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 2,029 F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | PurchaseCommon Stock | 332,566 | $15.00 | $4,988,490.00 |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 3 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 880,214 F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionCommon Stock | 1,262 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 2 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 1,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4 · ownership.nature: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 19:46 UTC | LB PHARMACEUTICALS INC LBRX · Entity 4678 | ConversionCommon Stock | 547,648 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-204935 · ownership.xml · nonDerivative · entry 1 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Belldegrun Arie · CIK 0001296549 · 10% owner Vida Ventures Management Co. LLC · CIK 0001905615 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 547,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F1 · price: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2 · ownership.nature: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3 · ownership.nature: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 7,356,162 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 6 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,616,348 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-2 Redeemable Convertible Preferred Stock · Derivative | 8,830,901 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 5 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,940,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionSeries A-1 Redeemable Convertible Preferred Stock · Derivative | 4,401,771 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · derivative · entry 4 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 967,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.exercise_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F5 · derivative.expiration_date: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | PurchaseCommon Stock | 583 | $22.00 | $12,826.00 |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 3 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 583 F4 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | PurchaseCommon Stock | 252,553 | $22.00 | $5,556,166.00 |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 2 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 252,553 F3 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| February 12, 2024 Filed Feb 15, 2024 00:04 UTC | Kyverna Therapeutics, Inc. KYTX · Entity 5452 | ConversionCommon Stock | 4,523,924 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-015479 · ownership.xml · nonDerivative · entry 1 Vida Ventures, LLC · CIK 0001724489 · 10% owner Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 4,523,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F1 · price: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2 · ownership.nature: The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionSeries B Preferred Stock · Derivative | 21,310 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · derivative · entry 6 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 0 Underlying: Common Stock · 7,684 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionSeries B Preferred Stock · Derivative | 9,243,756 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · derivative · entry 5 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 0 Underlying: Common Stock · 3,333,245 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | PurchaseCommon Stock | 3,852 | $14.00 | $53,928.00 |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · nonDerivative · entry 4 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 11,536 F5 · price: On January 11, 2022, Vida III-A purchased 3,852 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering. F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | PurchaseCommon Stock | 1,671,148 | $14.00 | $23,396,072.00 |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · nonDerivative · entry 3 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 5,004,393 F4 · price: On January 11, 2022, Vida III purchased 1,671,148 shares of Common Stock of the Issuer at a price of $14.00 per share pursuant to an underwritten public offering. F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionCommon Stock | 7,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · nonDerivative · entry 2 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III-A, L.P. Disclosed balance after: 7,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F3 · ownership.nature: The shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 02:18 UTC | Vigil Neuroscience, Inc. VIGL · Entity 11675 | ConversionCommon Stock | 3,333,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-001657 · doc4.xml · nonDerivative · entry 1 Vida Ventures GP III, L.L.C. · CIK 0001855502 · 10% owner Vida Ventures III, L.P. · CIK 0001855504 · 10% owner Vida Ventures III-A, L.P. · CIK 0001855503 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures III, L.P. Disclosed balance after: 3,333,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") on a one-for-2.7732 basis upon the closing of the Issuer's initial public offering on January 11, 2022 and had no expiration date. F2 · ownership.nature: The shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C.("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.